{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:47:47Z","timestamp":1787312867537,"version":"build-2736575974"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"\n Objective<\/jats:title>\n To evaluate secukinumab (SEC) 300 mg and 150 mg vs placebo in a United States\u2013only population of biologic-na\u00efve patients with psoriatic arthritis (PsA).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n CHOICE was a double-blind, randomized controlled trial conducted in the US. Biologic-na\u00efve patients with PsA and psoriasis (PsO) were randomized 2:2:1 to SEC 300 mg (n = 103), SEC 150 mg (n = 103), or placebo (n = 52). The primary objective was to show superiority of SEC 300 mg vs placebo in American College of Rheumatology 20% (ACR20) response at week 16. Additional objectives included the effect of SEC on dactylitis, enthesitis, PsO, and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n ACR20 response rates at week 16 were higher with SEC 300 mg than with placebo (51.5% vs 23.1%; odds ratio 3.51 [95% CI 1.65-7.45];\n P<\/jats:italic>\n = 0.001). SEC 300 mg also led to greater ACR50\/70 responses and improvements in other variables vs placebo. Responses were generally sustained over time. Patients with inadequate response to SEC 150 mg at weeks 16, 28, or 40 who received dose escalation to 300 mg experienced improved clinical response after uptitration. The most common adverse events were upper respiratory tract infections and diarrhea. No inflammatory bowel disease was reported or new safety signals observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n SEC 300 mg led to rapid and significant improvements over placebo in symptoms of PsA in this heavier population of US-only, biologic-na\u00efve patients. Findings were consistent with previous studies and suggest that SEC 300 mg is a safe and efficacious first-line biologic treatment for patients with PsA. [ClinicalTrials.gov:\n NCT02798211<\/jats:ext-link>\n ]\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3899\/jrheum.210912","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T08:25:20Z","timestamp":1650011120000},"page":"894-902","source":"Crossref","is-referenced-by-count":18,"title":["Secukinumab in United States Biologic-Na\u00efve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study"],"prefix":"10.3899","volume":"49","author":[{"given":"Tien","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-185X","authenticated-orcid":false,"given":"Melvin","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Kianifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chauncy","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Calheiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chambenoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2022072810450898000_49.8.894.1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022072810450898000_49.8.894.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"2022072810450898000_49.8.894.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2022072810450898000_49.8.894.4","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022072810450898000_49.8.894.5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2022072810450898000_49.8.894.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"2022072810450898000_49.8.894.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"2022072810450898000_49.8.894.8","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"2022072810450898000_49.8.894.9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000152"},{"key":"2022072810450898000_49.8.894.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2022072810450898000_49.8.894.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2022072810450898000_49.8.894.12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022072810450898000_49.8.894.13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2022072810450898000_49.8.894.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2022072810450898000_49.8.894.15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"2022072810450898000_49.8.894.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2022072810450898000_49.8.894.17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5 year efficacy and safety results from the phase 3 FUTURE 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2022072810450898000_49.8.894.18","unstructured":"Kivitz A , Kremer J , Legerton C , . Efficacy of secukinumab in a US patient population with psoriatic arthritis: a subgroup analysis of the phase 3 FUTURE studies [abstract]. Arthritis Rheumatol 2019;71 Suppl 10."},{"key":"2022072810450898000_49.8.894.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.008"},{"key":"2022072810450898000_49.8.894.20","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/acr.23460","article-title":"Value of the Routine Assessment of Patient Index Data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2022072810450898000_49.8.894.21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/RHU.0000000000000630","article-title":"Routine Assessment of Patient Index Data 3 Score and Psoriasis Quality of Life assess complementary yet different aspects of patient-reported outcomes in psoriasis and psoriatic arthritis","volume":"24","author":"Vakil-Gilani","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2022072810450898000_49.8.894.22","unstructured":"Gottlieb AB , Mease PJ , Kirkham B , . Secukinumab efficacy in psoriatic arthritis: individual patient meta-analysis of four phase 3 trials in 2049 patients [abstract]. Arthritis Rheumatol 2018;70 Suppl 10."},{"key":"2022072810450898000_49.8.894.23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40744-021-00337-5","article-title":"Secukinumab efficacy on psoriatic arthritis GRAPPA-OMERACT core domains in patients with or without prior tumor necrosis factor inhibitor use: pooled analysis of four phase 3 studies","volume":"8","author":"Orbai","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2022072810450898000_49.8.894.24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2022072810450898000_49.8.894.25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022072810450898000_49.8.894.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140882"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T13:49:17Z","timestamp":1659016157000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,7,28]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.3899\/jrheum.210912"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210912","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}